CompletedNot Applicable

Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care

United States1,001 participantsStarted 2018-03-30

Plain-language summary

This clinical trial studies universal screening for deoxyribonucleic acid (DNA) mismatch repair deficiency in patients with endometrial cancer, mutations in the genes responsible for Lynch syndrome (inherited forms of endometrial cancers) and other DNA changes that could help guide treatment strategies. Universal tumor DNA sequencing may help doctors better understand how to personalize care, increase length of life, and increase quality of life in patients with endometrial cancer and their relatives.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult women who had a hysterectomy or diagnostic biopsy proving endometrial adenocarcinoma (any stage) between 10/1/2017 and 4/30/2020, and received care at one of the participating hospitals * Adult relatives of the EC patients found to have LS Exclusion Criteria: * Individuals must be able to speak and read English; non-English speaking individuals will be excluded * Individuals must be able to consent for themselves; those who are unable to consent for themselves for any reason will be excluded * Prisoners will be specifically excluded from participation in the study * Women who have uterine sarcomas are excluded * Pregnant women are not eligible for the study

What they're measuring

Incidence of endometrial cancer patients with Lynch syndrome

Timeframe: Up to 3 years

Incidence of tumors with microsatellite instability and/or somatic POLE mutations

Timeframe: Up to 3 years

Trial details

NCT IDNCT03460483

SponsorOhio State University Comprehensive Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-15